| LDR | | 01612nmm uu200421 4500 |
| 001 | | 000000332010 |
| 005 | | 20240805165831 |
| 008 | | 181129s2018 |||||||||||||||||c||eng d |
| 020 | |
▼a 9780438077485 |
| 035 | |
▼a (MiAaPQ)AAI10826710 |
| 035 | |
▼a (MiAaPQ)indiana:15258 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 248032 |
| 082 | 0 |
▼a 616.99 |
| 100 | 1 |
▼a Pulliam, Nicholas. |
| 245 | 13 |
▼a An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-Mutations. |
| 260 | |
▼a [S.l.] :
▼b Indiana University.,
▼c 2018 |
| 260 | 1 |
▼a Ann Arbor :
▼b ProQuest Dissertations & Theses,
▼c 2018 |
| 300 | |
▼a 186 p. |
| 500 | |
▼a Source: Dissertation Abstracts International, Volume: 79-11(E), Section: B. |
| 500 | |
▼a Adviser: Kenneth P. Nephew. |
| 502 | 1 |
▼a Thesis (Ph.D.)--Indiana University, 2018. |
| 520 | |
▼a Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are primarily effective against BRCA1/2-mutated ovarian and breast cancers, but resistance due to reversion of mutated BRCA1/2 and other mechanisms is common. Based on previous reports demon |
| 590 | |
▼a School code: 0093. |
| 650 | 4 |
▼a Oncology. |
| 650 | 4 |
▼a Molecular biology. |
| 650 | 4 |
▼a Cellular biology. |
| 690 | |
▼a 0992 |
| 690 | |
▼a 0307 |
| 690 | |
▼a 0379 |
| 710 | 20 |
▼a Indiana University.
▼b Biochemistry. |
| 773 | 0 |
▼t Dissertation Abstracts International
▼g 79-11B(E). |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 0093 |
| 791 | |
▼a Ph.D. |
| 792 | |
▼a 2018 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T14998929
▼n KERIS |
| 980 | |
▼a 201812
▼f 2019 |
| 990 | |
▼a 관리자 |